Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection

Clinical and Experimental Medicine

Volumn 14, Issue 1, 2014, Pages 35-43

  Han, Qunying ^a   Li, Na ^a   Zhu, Qianqian ^a   Li, Zhu ^a   Zhang, Guoyu ^a   Chen, Jinghong ^a   Lv, Yi ^a   Wang, Yawen ^a   Liu, Zhengwen ^a   Hao, Chunqiu ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Diagnoses; Disease activity; Hepatitis B virus; Infection; Infection phase; sHLA G

Indexed keywords

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B, CHRONIC; HLA-G ANTIGENS; HUMANS; MALE; MIDDLE AGED; SERUM; YOUNG ADULT;

EID: 84895098939     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0214-5     Document Type: Article

References (49)

1. Fattovich G, Brollo L, Giustina G et al (1991) Natural history and prognostic factors for chronic hepatitis type B. Gut 32:294-298
2. Locarnini S (2004) Molecular virology of hepatitis B virus. Semin Liver Dis 24(Suppl 1):3-10
3. Liaw YF, Chu CM (2009) Hepatitis B virus infection. Lancet 373:582-592
4. European Association For The Study Of The Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227-242
5. Hsu YS, Chien RN, Yeh CT et al (2002) Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35:1522-1527
6. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF (2004) Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 116:829-834
7. Fattovich G, Bortolotti F, Donato F (2008) Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48:335-352
8. Chu CM, Liaw YF (2007) Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 1:311-315
9. Hadziyannis SJ, Vassilopoulos D (2001) Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617-624
10. Liu J, Yang HI, Lee MH et al (2010) Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 139:474-482
11. Chen CJ, Yang HI (2011) Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 26:628-638
12. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192:921-930
13. Fisicaro P, Valdatta C, Boni C et al (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974-982
14. Mondelli MU, Varchetta S, Oliviero B (2010) Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest 40:851-863
15. TrehanPati N, Geffers R, Sukriti S et al (2009) Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 49:781-790
16. Das A, Hoare M, Davies N et al (2008) Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205:2111-2124
17. Op den Brouw ML, Binda RS, van Roosmalen MH et al (2009) Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126:280-289
18. Stoop JN, van der Molen RG, Baan CC et al (2005) Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41:771-778
19. Xu D, Fu J, Jin L et al (2006) Circulating and liver resident CD4+ CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177:739-747
20. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R (1990) A class I antigen, HLA-G, expressed in human trophoblasts. Science 248:220-223
21. Rouas-Freiss N, Gonçalves RM, Menier C, Dausset J, Carosella ED (1997) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 94:11520-11525
22. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N (2008) HLA-G: from biology to clinical benefits. Trends Immunol 29:125-132
23. Baricordi OR, Stignani M, Melchiorri L, Rizzo R (2008) HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets 7:67-74
24. Lin A, Chen HX, Zhu CC et al (2010) Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 14:2162-2171
25. Monneret G, Voirin N, Krawice-Radanne I et al (2007) Soluble human leukocyte antigen-G5 in septic shock: marked and persisting elevation as a predictor of survival. Crit Care Med 35:1942-1947
26. Rosado S, Perez-Chacon G, Mellor-Pita S et al (2008) Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum Immunol 69:9-15
27. Weng PJ, Fu YM, Ding SX, Xu DP, Lin A, Yan WH (2011) Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection. Hum Immunol 72:406-411
28. Donaghy L, Gros F, Amiot L et al (2007) Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. Clin Exp Immunol 147:236-240
29. Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED (2000) Implication of HLA-G molecule in heart-graft acceptance. Lancet 355:2138
30. Carosella ED, Dausset J, Kirszenbaum M (1996) HLA-G revisited. Immunol Today 17:407-409
31. Le Gal FA, Riteau B, Sedlik C et al (1999) HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11:1351-1356
32. Contini P, Ghio M, Poggi A et al (2003) Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33:125-134
33. Rouas-Freiss N, Khalil-Daher I, Riteau B et al (1999) The immunotolerance role of HLA-G. Semin Cancer Biol 9:3-12
34. Bahri R, Hirsch F, Josse A et al (2006) Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176:1331-1339
35. Rajagopalan S, Bryceson YT, Kuppusamy SP et al (2006) Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 4:e9
36. Lok AS, McMahon BJ (2001) Chronic hepatitis B. Hepatology 34:1225-1241
37. Duan S, Zhang G, Han Q et al (2011) CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with -318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients. Mol Biol Rep 38:5125-5132
38. Fournel S, Aguerre-Girr M, Huc X et al (2000) Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 164:6100-6104
39. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED (2001) Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 98:12150-12155
40. Paul P, Cabestre FA, Ibrahim EC et al (2000) Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 61:1138-1149
41. Souto FJ, Crispim JC, Ferreira SC et al (2011) Liver HLA-G expression is associated with multiple clinical and histopathological forms of chronic hepatitis B virus infection. J Viral Hepat 18:102-105
42. Shi WW, Lin A, Xu DP et al (2011) Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection. Hum Immunol 72:1068-1073
43. Park Y, Park Y, Lim HS, Kim YS, Hong DJ, Kim HS (2012) Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Tissue Antigens 79:97-103
44. Brook MG, Karayiannis P, Thomas HC (1989) Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10:761-763
45. Chien RN, Liaw YF, Atkins M (1999) Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30:770-774
46. Amiot L, Ferrone S, Grosse-Wilde H, Seliger B (2011) Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 68:417-431
47. Wang Y, Ye Z, Meng XQ, Zheng SS (2011) Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 10:158-163
48. Cai MY, Xu YF, Qiu SJ et al (2009) Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res 15:4686-4693
49. Chen A, Shen Y, Xia M et al (2011) Expression of the nonclassical HLA class I and MICA/B molecules in human hepatocellular carcinoma. Neoplasma 58:371-376